Please enable JavaScript to continue using this application.

Compare $AKBA vs $TRDA | Chartloom

Compare

$AKBA vs $TRDA

Akebia Therapeutics Inc · Entrada Therapeutics Inc

AKBA

Akebia Therapeutics Inc

TRDA

Entrada Therapeutics Inc

Compare $AKBA vs $TRDA

Comparing Akebia Therapeutics Inc and Entrada Therapeutics Inc

AKBAAkebia Therapeutics Inc

TRDAEntrada Therapeutics Inc

AKBAAkebia Therapeutics Inc

Market cap

$215M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

1.35x

Rev growth (TTM)

7.5%

YTD performance

-48.3%

52W performance

-71.9%

FCF yield

13.7%

TRDAEntrada Therapeutics Inc

Market cap

$220M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

5.15x

Rev growth (TTM)

-94.1%

YTD performance

-43.6%

52W performance

-8.0%

FCF yield

-61.4%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

AKBA

TRDA

Detailed metrics comparison

AKBA

Akebia Therapeutics Inc

TRDA

Entrada Therapeutics Inc

Market Cap

AKBA$215M

TRDA$220M

Enterprise Value

AKBA$252M

TRDA$121M

Price

AKBA$0.80

TRDA$5.67

P/E Ratio

AKBAN/A

TRDAN/A

P/S Ratio

AKBA0.98x

TRDA46.97x

EV/Sales

AKBA1.15x

TRDA25.79x

EV/EBITDA

AKBA49.22x

TRDA15.47x

P/B Ratio

AKBA9.58x

TRDA0.90x

P/FCF Ratio

AKBA7.30x

TRDAN/A

EV/FCF

AKBA8.54x

TRDA-0.89x

PEG Ratio

AKBAN/A

TRDAN/A

Forward P/E (NTM)

AKBAN/A

TRDAN/A

Forward P/S (NTM)

AKBA1.35x

TRDA5.15x

Revenue (TTM)

AKBA$219M

TRDA$5M

Revenue Growth (YoY)

AKBA7.5%

TRDA-94.1%

Forward Rev Growth

AKBA-33.0%

TRDA124.9%

Gross Margin (TTM)

AKBA81.5%

TRDA0.0%

Operating Margin (TTM)

AKBA0.0%

TRDA0.0%

EBITDA Margin (TTM)

AKBA-1.9%

TRDA-3686.8%

Net Margin (TTM)

AKBA-13.5%

TRDA-3537.7%

FCF Margin (TTM)

AKBA13.4%

TRDA-2883.2%

Net Income (TTM)

AKBA$-30M

TRDA$-166M

FCF (TTM)

AKBA$29M

TRDA$-135M

EPS (TTM)

AKBA-$0.11

TRDA-$3.93

ROE (TTM)

AKBA-9374.0%

TRDA-5761.0%

ROA (TTM)

AKBA-817.0%

TRDA-4654.0%

ROIC (TTM)

AKBA-1321.0%

TRDA-5761.0%

Cash

AKBA$156M

TRDA$99M

Debt

AKBA$192M

TRDA$0

Net Cash/Debt

AKBA$-37M

TRDA$99M

Current Ratio (TTM)

AKBA1.43x

TRDA10.89x

Quick Ratio (TTM)

AKBA1.31x

TRDA10.47x

Debt/Equity (TTM)

AKBA7.69x

TRDA0.00x

Debt/Assets (TTM)

AKBA0.0%

TRDA0.0%

Interest Coverage (TTM)

AKBAN/A

TRDAN/A

Net Debt/EBITDA (TTM)

AKBA0.00x

TRDA0.00x

Beta

AKBA0.20

TRDA-0.22

52W Performance

AKBA-71.9%

TRDA-8.0%

YTD Performance

AKBA-48.3%

TRDA-43.6%

% from 52W High

AKBA-75.0%

TRDA-65.5%

% from 52W Low

AKBA0.0%

TRDA10.1%

Asset Turnover (TTM)

AKBA0.60x

TRDA0.01x

FCF Yield (TTM)

AKBA13.7%

TRDA-61.4%

Earnings Yield (TTM)

AKBA-13.8%

TRDA-75.3%

Dividend Yield (TTM)

AKBAN/A

TRDAN/A

Rule of 40

AKBA21.0

TRDA-2,977.3

EV/GP/RG

AKBAN/A

TRDAN/A

Ticker research

View AKBA research View TRDA research

Metric	AKBA Akebia Therapeutics Inc	TRDA Entrada Therapeutics Inc
Market & Valuation
Market Cap	$215M	$220M
Enterprise Value	$252M	$121M
Price	$0.80	$5.67
P/E Ratio	N/A	N/A
P/S Ratio	0.98x	46.97x
EV/Sales	1.15x	25.79x
EV/EBITDA	49.22x	15.47x
P/B Ratio	9.58x	0.90x
P/FCF Ratio	7.30x	N/A
EV/FCF	8.54x	-0.89x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	1.35x	5.15x
Revenue & Growth
Revenue (TTM)	$219M	$5M
Revenue Growth (YoY)	7.5%	-94.1%
Forward Rev Growth	-33.0%	124.9%
Profitability
Gross Margin (TTM)	81.5%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-1.9%	-3686.8%
Net Margin (TTM)	-13.5%	-3537.7%
FCF Margin (TTM)	13.4%	-2883.2%
Net Income (TTM)	$-30M	$-166M
FCF (TTM)	$29M	$-135M
EPS (TTM)	-$0.11	-$3.93
ROE (TTM)	-9374.0%	-5761.0%
ROA (TTM)	-817.0%	-4654.0%
ROIC (TTM)	-1321.0%	-5761.0%
Financial Health
Cash	$156M	$99M
Debt	$192M	$0
Net Cash/Debt	$-37M	$99M
Current Ratio (TTM)	1.43x	10.89x
Quick Ratio (TTM)	1.31x	10.47x
Debt/Equity (TTM)	7.69x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.20	-0.22
52W Performance	-71.9%	-8.0%
YTD Performance	-48.3%	-43.6%
% from 52W High	-75.0%	-65.5%
% from 52W Low	0.0%	10.1%
Efficiency & Yields
Asset Turnover (TTM)	0.60x	0.01x
FCF Yield (TTM)	13.7%	-61.4%
Earnings Yield (TTM)	-13.8%	-75.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	21.0	-2,977.3
EV/GP/RG	N/A	N/A
Ticker research	View AKBA research	View TRDA research

Valuation

P/S Ratio

AKBA

0.98x

TRDA

46.97x

EV/FCF

TRDA

-0.89x

AKBA

8.54x

Growth & revenue

Revenue Growth TTM

AKBA

7.5%

TRDA

-94.1%

Forward Revenue Growth

TRDA

124.9%

AKBA

-33.0%

Profitability & performance

Gross Margin

AKBA

81.5%

TRDA

0.0%

ROE

TRDA

-5761.0%

AKBA

-9374.0%

FCF Yield %

AKBA

13.7%

TRDA

-61.4%

52-Week Performance

TRDA

-8.0%

AKBA

-71.9%

Detailed metrics comparison

AKBA

Akebia Therapeutics Inc

TRDA

Entrada Therapeutics Inc

Market Cap

AKBA$215M

TRDA$220M

Enterprise Value

AKBA$252M

TRDA$121M

Price

AKBA$0.80

TRDA$5.67

P/E Ratio

AKBAN/A

TRDAN/A

P/S Ratio

AKBA0.98x

TRDA46.97x

EV/Sales

AKBA1.15x

TRDA25.79x

EV/EBITDA

AKBA49.22x

TRDA15.47x

P/B Ratio

AKBA9.58x

TRDA0.90x

P/FCF Ratio

AKBA7.30x

TRDAN/A

EV/FCF

AKBA8.54x

TRDA-0.89x

PEG Ratio

AKBAN/A

TRDAN/A

Forward P/E (NTM)

AKBAN/A

TRDAN/A

Forward P/S (NTM)

AKBA1.35x

TRDA5.15x

Revenue (TTM)

AKBA$219M

TRDA$5M

Revenue Growth (YoY)

AKBA7.5%

TRDA-94.1%

Forward Rev Growth

AKBA-33.0%

TRDA124.9%

Gross Margin (TTM)

AKBA81.5%

TRDA0.0%

Operating Margin (TTM)

AKBA0.0%

TRDA0.0%

EBITDA Margin (TTM)

AKBA-1.9%

TRDA-3686.8%

Net Margin (TTM)

AKBA-13.5%

TRDA-3537.7%

FCF Margin (TTM)

AKBA13.4%

TRDA-2883.2%

Net Income (TTM)

AKBA$-30M

TRDA$-166M

FCF (TTM)

AKBA$29M

TRDA$-135M

EPS (TTM)

AKBA-$0.11

TRDA-$3.93

ROE (TTM)

AKBA-9374.0%

TRDA-5761.0%

ROA (TTM)

AKBA-817.0%

TRDA-4654.0%

ROIC (TTM)

AKBA-1321.0%

TRDA-5761.0%

Cash

AKBA$156M

TRDA$99M

Debt

AKBA$192M

TRDA$0

Net Cash/Debt

AKBA$-37M

TRDA$99M

Current Ratio (TTM)

AKBA1.43x

TRDA10.89x

Quick Ratio (TTM)

AKBA1.31x

TRDA10.47x

Debt/Equity (TTM)

AKBA7.69x

TRDA0.00x

Debt/Assets (TTM)

AKBA0.0%

TRDA0.0%

Interest Coverage (TTM)

AKBAN/A

TRDAN/A

Net Debt/EBITDA (TTM)

AKBA0.00x

TRDA0.00x

Beta

AKBA0.20

TRDA-0.22

52W Performance

AKBA-71.9%

TRDA-8.0%

YTD Performance

AKBA-48.3%

TRDA-43.6%

% from 52W High

AKBA-75.0%

TRDA-65.5%

% from 52W Low

AKBA0.0%

TRDA10.1%

Asset Turnover (TTM)

AKBA0.60x

TRDA0.01x

FCF Yield (TTM)

AKBA13.7%

TRDA-61.4%

Earnings Yield (TTM)

AKBA-13.8%

TRDA-75.3%

Dividend Yield (TTM)

AKBAN/A

TRDAN/A

Rule of 40

AKBA21.0

TRDA-2,977.3

EV/GP/RG

AKBAN/A

TRDAN/A

Ticker research

View AKBA research View TRDA research

Metric	AKBA Akebia Therapeutics Inc	TRDA Entrada Therapeutics Inc
Market & Valuation
Market Cap	$215M	$220M
Enterprise Value	$252M	$121M
Price	$0.80	$5.67
P/E Ratio	N/A	N/A
P/S Ratio	0.98x	46.97x
EV/Sales	1.15x	25.79x
EV/EBITDA	49.22x	15.47x
P/B Ratio	9.58x	0.90x
P/FCF Ratio	7.30x	N/A
EV/FCF	8.54x	-0.89x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	1.35x	5.15x
Revenue & Growth
Revenue (TTM)	$219M	$5M
Revenue Growth (YoY)	7.5%	-94.1%
Forward Rev Growth	-33.0%	124.9%
Profitability
Gross Margin (TTM)	81.5%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-1.9%	-3686.8%
Net Margin (TTM)	-13.5%	-3537.7%
FCF Margin (TTM)	13.4%	-2883.2%
Net Income (TTM)	$-30M	$-166M
FCF (TTM)	$29M	$-135M
EPS (TTM)	-$0.11	-$3.93
ROE (TTM)	-9374.0%	-5761.0%
ROA (TTM)	-817.0%	-4654.0%
ROIC (TTM)	-1321.0%	-5761.0%
Financial Health
Cash	$156M	$99M
Debt	$192M	$0
Net Cash/Debt	$-37M	$99M
Current Ratio (TTM)	1.43x	10.89x
Quick Ratio (TTM)	1.31x	10.47x
Debt/Equity (TTM)	7.69x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.20	-0.22
52W Performance	-71.9%	-8.0%
YTD Performance	-48.3%	-43.6%
% from 52W High	-75.0%	-65.5%
% from 52W Low	0.0%	10.1%
Efficiency & Yields
Asset Turnover (TTM)	0.60x	0.01x
FCF Yield (TTM)	13.7%	-61.4%
Earnings Yield (TTM)	-13.8%	-75.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	21.0	-2,977.3
EV/GP/RG	N/A	N/A
Ticker research	View AKBA research	View TRDA research